DNA Collection Aids Arrests — But What About Privacy?
By Noreen Moustafa,
Aljazeera America
| 02. 21. 2014
In this week’s episode of “TechKnow,” we highlight the latest advances in forensic technology that are helping law enforcement agencies identify suspects and solve crimes with increasing accuracy. Cases that were left cold for years are being revisited with fresh eyes—and, more importantly, fresh technology. Where we have seen some of the largest leaps in the past decade is in the analysis of contact trace DNA or “Touch DNA.” A person sheds about 400,000 skin cells per day, and with smaller and smaller samples required to make an accurate match, it is becoming more difficult to commit a truly untraceable crime.
But in order to match crimes up with criminals based on trace amounts of DNA, it also requires expanding and centralizing local, state, and national DNA databases used by law enforcement.
Last June,
the Supreme Court ruled 5-4 that it was constitutional to take DNA swabs from people who have been arrested for “serious crimes” without getting a warrant or waiting for a conviction. These DNA samples can be added to a database and can be used to...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...